What we have learned from the myriad trials

Journal of Nutrition, Health and Aging

Volumn 13, Issue 4, 2009, Pages 362-364

  Hendrix, S B ^a   Wilcock, G K ^a  

^a Pentara Corporation   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN E4; CHOLINESTERASE INHIBITOR; MEMANTINE; PLACEBO; TARENFLURBIL;

ALZHEIMER DISEASE; ALZHEIMER DISEASE ASSESSMENT SCALE COGNITIVE SUBSCALE; ALZHEIMER DISEASE COOPERATIVE STUDY ACTIVITIES OF DAILY LIVING SCALE; ARTICLE; CLINICAL ASSESSMENT TOOL; CLINICAL DEMENTIA RATING SCALE SUM OF BOXES; CLINICAL TRIAL; DRUG MEGADOSE; HUMAN; LOW DRUG DOSE; MINI MENTAL STATE EXAMINATION; NEUROIMAGING; OUTCOME ASSESSMENT; PRIORITY JOURNAL;

ALZHEIMER DISEASE; FLURBIPROFEN; HUMANS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RESEARCH DESIGN;

EID: 65249119613     PISSN: 12797707     EISSN: None     Source Type: Journal    
DOI: 10.1007/s12603-009-0044-7     Document Type: Article

References (11)

1. Wilcock GK, Black SE, Hendrix SB, Zavitz KH, Swabb EA, Laughlin MA, Tarenflurbil Phase II Study investigators. Efficacy and safety of tarenflurbil in mild to moderate Alzheimer's disease: a randomised phase II trial. Lancet Neurol. 2008 Jun;7(6):483-93.
2. Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12: 189-98.
3. Green R, Schneider L, Hendrix S, Zavitz K, Swabb E. "O3-04-01: Safety and efficacy of tarenflurbil in subjects with mild Alzheimer's disease: Results from an 18-month multi-center phase 3 trial." Alzheimer Dement 2008; 4, T165 (abstr).
4. Rosen WG, Mohs RC, Davis KL. A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-64.
5. Mohs RC, Knopman D, Petersen RC, et al. Development of cognitive instruments for use in clinical trials of antidementia drugs: additions to the Alzheimer's disease assessment scale that broaden its scope. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2): S13-21.
6. Galasko D, Bennett D, Sano M, et al. An inventory to assess activities of daily living for clinical trials in Alzheimer's disease. The Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11 (suppl 2): S33-39.
7. Hughes CP, Berg L, Danziger WL, Coben LA, Martin RL. A new clinical scale for the staging of dementia. Br J Psychiatry 1982; 140: 566-72.
8. Jackson M, Hendrix S, Zavitz K, Green R, Schneider L, Swabb E. P4-376: A phase 3 multicenter trial of tarenflurbil in subjects with mild dementia of the Alzheimer's type (Act-Earli-AD): Rationale and methodology. Alzheimer Dement 2008, 4, T784 (abstr).
9. Hendrix S, Gutin A, Zavitz K, Carron G, Laughlin M, Horton S. Modification of the staggered start and randomized withdrawal clinical trial designs: toward a practical demonstration of disease modification in Alzheimer's disease (AD). Alzheimer Dement 2007; 3:S160 (abstr).
10. Chuang-Stein C. Seize the opportunities Pharmaceutical Statistics 2004; 3, 157-159
11. Pocock S, White I. Trials stopped early: too good to be true? Lancet 1999; 353(9157):943-4.